Aglaia BioMedical Ventures

1 Decision Maker · 1 Verified Contact & Email Format

📍 Bilthoven, Utrecht, undefinedNetherlandsFinance & Banking🗓 Est. 2003👥 Under 10 employees

About Aglaia BioMedical Ventures

Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities

Email Format

{last_name}@aglaia-biomedical.com — 100.0%

smith@aglaia-biomedical.com

Leadership & Decision Makers

Contact details of 1 Aglaia BioMedical Ventures decision makers

Mark Krul

Founder and Director
  • Work email

    k**l@aglaia-biomedical.com

General Emails

General company emails, e.g. customer support lines

    info@aglaia-biomedical.com

    General Inquiries

    kr@aglaia-biomedical.com

    Unclassified inbox

Similar Companies like Aglaia BioMedical Ventures

Finance & Banking · New York, NY · Est. 1985 · Under 10 employees · $500M–$1B

HQ: New York, NY

Finance & Banking · Boston, MA · Est. 2015 · Under 10 employees · $1B–$1000B

HQ: Boston, MA

Wipro Ventures

wipro.com
Finance & Banking · Mountain View, CA · Est. 2015 · Under 10 employees

HQ: Mountain View, CA

T-Mobile Ventures

t-mobile.com
Finance & Banking · Bellevue, WA · Est. 2018 · Under 10 employees

HQ: Bellevue, WA

IBM Ventures

ibm.com
Finance & Banking · Armonk, New York, United States · Est. 2020 · Under 10 employees

HQ: Armonk, New York, United States

Explore similar firms in the Finance & Banking sector

Company Info

Last updated: 31/07/2025

+31 30 229 6090

Bilthoven, Utrecht, undefinedNetherlands

Employees: 1-10
Venture Stage: Early Stage Venture
Founded Date: 2003
Number of Exits: 1
Operating Status: Active
Investor Type: Venture Capital
Phone Number: +31 30 229 6090
Last Investment Activity: Oct 7, 2021
Investments Activity: Oct 7, 2021 Feb 9, 2021 Jun 26, 2018
Early-Stage Investments: Yes

Our service is undergoing beta testing, and you can get all the information that is closed on this page for free by registering. You will not need to provide your credit/debit card details.